On March 8, 2022 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it is scheduled to present new preclinical data on PH-894, Phio’s self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4), in an in-person poster session at the AACR (Free AACR Whitepaper) Annual Meeting 2022, which is being held in New Orleans, Louisiana, from April 8-13, 2022 (Press release, Phio Pharmaceuticals, MAR 8, 2022, View Source [SID1234609660]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details are as follows:

Title: Local administration of BRD4-targeting self-delivering RNAi (PH-894) provides abscopal efficacy toward untreated distal tumors and potentiates the efficacy of systemic anti-PD-1 antibody therapy

Author: Benjamin Cuiffo, et al.

Abstract Number: 4237

Session Date and Time: Wednesday Apr 13, 2022 9:00 AM – 12:30 PM

Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 38

The poster presentation will be accessible in person and virtually and will also be made available on the "Investors – Events and Presentations" section of the Company’s website (click here).